Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 9Fallopian Tube Neoplasms 8Neoplasms 6Prostatic Neoplasms 5Carcinoma, Ovarian Epithelial 5Recurrence 3Pancreatic Neoplasms 3Breast Neoplasms 3Urinary Bladder Neoplasms 2Metastatic Castration Resistant Prostate Cancer 2Colorectal Neoplasms 2Carcinoma, Transitional Cell 2Uterine Cervical Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Solid Tumor 1Sarcoma 1Primary Myelofibrosis 1Pathologic Complete Response 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Multiple Myeloma 1Mental Retardation, X-Linked, With Or Without Seizures, Arx-Related 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Lung Neoplasms 1

Interventions

serabelisib 1sapanisertib 1rucaparib 1Paclitaxel 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Endometrioid × rucaparib × Clear all
NCT03824704 2023-06-12

A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)

pharmaand GmbH

Phase 2 Terminated
1 enrolled 7 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Carcinoma, Endometrioid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡